OBJECTIVES: To perform pharmacoeconomic analysis of golimumab (GOL) vs adalimumab (ADA) and infiliximab (INF) for rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) in Russia METHODS: Indirect comparison demonstrated that compared drugs have similar efficacy and safety. Cost-minimization analysis was performed to compare the cost for 1-year treatment with GOL, ADA and INF in doses according to the approved recommendations. Expected cost for treating all eligible patients with RA, AS and PA with TNF-α-inhibitors in Russia were calculated in a model, assuming that INF is used in the 1st line therapy during one year and ADA or GOL in the 2d line therapy during the 2d year. Number of patients to be treated with TNF-α-inhibitors was calculated based on state statistical data and data on the percentage of patients who do not respond to therapy with synthetic disease-modifying antirheumatic drugs (DMARDs) and first-line biologic DMARDs from clinical trials.  RESULTS: INF dosing regimen is different for RA and other rheumatic diseases, 1 year treatment with INF costs €16,212 for RA and €24,319 for AS and PA. GOL and ADA have the same dosing regimen for all rheumatic diseases and costs €16,544 and €24,243 per year correspondingly. If all eligible patients with rheumatic diseases in Russia receive biologic DMARDs when necessary, treatment with GOL in the 2d line is less expensive than ADA, difference in costs is €89,062,427 (for all eligible patients per year). It allows treating additional 4959 patients RA , 278 AS patients and 147 PA patients per year.  CONCLUSIONS: GOL is cost-saving vs ADA for the 2d line therapy of rheumatic diseases in Russia. 1-year treatment with GOL is less expensive that INF for AS and PA and may be considered as the 1st line option.